摘要
目的探讨晚期卵巢癌患者行紫杉醇联合卡铂新辅助化疗的近期疗效及对不良反应的影响。方法58例晚期卵巢癌患者,选择随机数字表法分为对照组和观察组,每组29例。对照组实施顺铂、环磷酰胺联合化疗方案治疗,观察组实施紫杉醇联合卡铂新辅助化疗方案治疗。比较两组患者的治疗效果,卵巢血流参数[收缩期最大血流流速(PSV)、血流灌注指数(PI)、血管阻力指数(RI)]改善情况,基质金属蛋白酶-2与血管内皮生长因子水平,不良反应发生情况。结果治疗后,观察组的治疗总缓解率为89.66%,高于对照组的65.52%,差异具有统计学意义(P<0.05)。治疗后,两组患者的PSV低于本组治疗前,PI、RI高于本组治疗前,且观察组患者的PSV(18.48±2.02)cm/s低于对照组的(22.45±2.88)cm/s,PI(0.72±0.10)、RI(1.63±0.15)高于对照组的(0.43±0.08)、(1.02±0.14),差异具有统计学意义(P<0.05)。观察组的基质金属蛋白酶-2(241.87±18.97)ng/ml、血管内皮生长因子(172.20±14.39)pg/ml均低于对照组的(289.42±21.97)ng/ml、(256.29±15.90)pg/ml,差异具有统计学意义(P<0.05)。观察组的不良反应发生率为10.34%,低于对照组的34.48%,差异具有统计学意义(P<0.05)。结论晚期卵巢癌患者行紫杉醇联合卡铂新辅助化疗的近期疗效显著,可改善患者的卵巢血流参数,降低基质金属蛋白酶-2与血管内皮生长因子水平,同时可减少不良反应发生,建议广泛应用于临床中。
Objective To discuss the effect of neoadjuvant chemotherapy with paclitaxel and carboplatin on short-term efficacy and adverse reactions in patients with advanced ovarian cancer.Methods A total of 58 patients with advanced ovarian cancer were divided into control group and observation group according to the random numerical table,with 29 cases in each group.The control group was treated with a combination chemotherapy of cisplatin and cyclophosphamide,and the observation group was treated with a neoadjuvant chemotherapy of paclitaxel combined with carboplatin.Both groups were compared in terms of therapeutic effect,improvement of ovarian blood flow parameters[peak systolic velocity(PSV),perfusion index(PI),resistance index(RI)],levels of matrix metalloproteinase-2 and vascular endothelial growth factor,and occurrence of adverse reactions.Results After treatment,the total remission rate of 89.66%in the observation group was higher than that of 65.52%in the control group,and the difference was statistically significant(P<0.05).After treatment,PSV in both groups was lower than that before treatment in this group,and PI and RI were higher than those before treatment in this group;PSV of(18.48±2.02)cm/s in the observation group was lower than that of(22.45±2.88)cm/s in the control group;PI of(0.72±0.10)and RI of(1.63±0.15)in the observation group were higher than those of(0.43±0.08)and(1.02±0.14)in the control group;the differences were statistically significant(P<0.05).The matrix metalloproteinase-2 of(241.87±18.97)ng/ml and vascular endothelial growth factor of(172.20±14.39)pg/ml in the observation group were lower than those of(289.42±21.97)ng/ml and(256.29±15.90)pg/ml in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 10.34%,which was lower than that of 34.48%in the control group,and the difference was statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy with paclitaxel and carboplatin has significant short-term efficacy in patients with advanced ovarian cancer,which can improve the ovarian blood flow parameters of patients,reduce the levels of matrix metalloproteinase-2 and vascular endothelial growth factor,and reduce the occurrence of adverse reactions at the same time,so it is recommended to be widely used in clinical practice.
作者
侯美英
HOU Mei-ying(Department of Hematology and Oncology,Jinxiang County People's Hospital,Jining 272200,China)
出处
《中国现代药物应用》
2023年第13期132-135,共4页
Chinese Journal of Modern Drug Application
关键词
紫杉醇
卡铂
新辅助化疗
晚期卵巢癌
近期疗效
不良反应
Paclitaxel
Carboplatin
Neoadjuvant chemotherapy
Advanced ovarian cancer
Short-term efficacy
Adverse reactions
